AbbVie Inc is a research-based biopharmaceutical company with a product portfolio spanning immunology, hematologic oncology, neuroscience, aesthetics, and eye care. The company operates through a business segment that is dedicated to the research and development, manufacturing, commercialization, and sale of innovative medicines and therapies. AbbVie’s immunology products such as Humira (adalimumab), Skyrizi (risankizumab), and Rinvoq (upadacitinib) address the unmet needs of patients with autoimmune diseases. Its oncology products – Imbruvica (ibrutinib) and Venclexta (venetoclax) – target complex and difficult-to-treat cancers. The company’s aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Neuroscience products include Vraylar (cariprazine), Duopa and Duodopa (carbidopa and levodopa), and Ubrelvy (ubrogepant). AbbVie’s eye care products, Lumigan (bimatoprost ophthalmic solution) and Alphagan (brimonidine tartrate ophthalmic solution) help preserve and protect patients’ vision.
AbbVie’s research and development capabilities led to the clinical development of numerous compounds (and complementary devices), including potential treatments for complex and life-threatening diseases.